Sandoz has completed the acquisition of the US biosimilar CIMERLI® (ranibizumab-eqrn) from Coherus BioSciences, Inc, ahead of anticipated timelines. The acquisition builds on the leading Sandoz ophthalmic platform in the US and lays an even stronger foundation for future product…
The Supervisory Board of Bayer AG has appointed Julio Triana (58) to Bayer’s Board of Management effective April 1, 2024. He will become President of the Consumer Health Division effective May 1, 2024, and succeed Heiko Schipper (54), who has…
Researchers at The University of Texas MD Anderson Cancer Center built a new atlas of lung cells, uncovering new cellular pathways and precursors in the development of lung adenocarcinoma, the most common type of lung cancer. These findings, published today…
AbbVie and OSE Immunotherapeutics, a clinical-stage immunotherapy company, today announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage. OSE-230 is a first-in-class monoclonal antibody designed to…
Viatris and Idorsia today announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to…
Merck will open a new, € 20 million distribution center in Cajamar, São Paulo, Brazil to better serve its Life Science customers in the region. The new space, which will be operational in late February, has an area of 13,000…
AstraZeneca today announced the successful completion of the acquisition of Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering AstraZeneca’s cell therapy ambition. The acquisition…
NORTH CHICAGO, Ill., Feb. 20, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael, AbbVie’s current president and chief operating officer, to succeed Richard A. Gonzalez as the company’s chief…
Gilead Sciences and CymaBay Therapeutics announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for…
Taygun Günay, currently serving as the Senior Vice President and Cluster Head for Russia and CIS at Bayer Consumer Health, has been appointed as the Senior Vice President and Sub Region Head for Eastern Europe, Middle East, Turkey & Africa.…